ITUS names Michael Catelani as its new CFO
Mr. Catelani is a seasoned executive with over 25 years of experience in finance, auditing, and operations.
Previously, Mr. Catelani cofounded Tacere Therapeutics, Inc., a privately held biotech company, and served as its Chairman, President & Chief Financial Officer until its sale.
Prior to Tacere, he served on the Board of Directors and was the Chief Financial Officer of Benitec Biopharma Limited, an Australian Stock Exchange-listed biotech company.
He was Vice President and Chief Financial Officer at Axon Instruments, a designer and manufacturer of instrumentation and software systems for biotechnology and diagnostics research.
Previously, he was the Vice President of Finance for Media Arts Group, Inc., an NYSE-listed company.
Mr. Catelani has also worked with several early stage start-ups in a variety of industries, including biotechnology, retail, waste water recovery, and distributed power generation, in both advisory and management roles and has served as a contract CFO to a number of established businesses in the biotech field.
He began his professional career at Ernst & Young and is a CPA. He received his BS degree in business administration, with a concentration in accountancy from Sacramento State University and earned his MBA from the University of California, Davis.
Mr. Catelani replaces Henry Herms, who will retire at the end of December after 21 years with the company. ■
LATEST MOVES FROM California
- Reed's appoints Stefan Freeman as interim CEO
- Heron Therapeutics appoints Robert E. Hoffman as CFO
- Penumbra appoints Bridget O'Rourke to board
- Adverum Biotechnologies adds Richard N. Spivey to board
- Lombard Medical appoints Kurt Lemvigh as CEO
More inside POST